Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Al Kalma is a pioneering healthcare joint venture formed in 2024 through a strategic partnership between UAE-based Burjeel Holdings and Colombia-based Keralty. The company is dedicated to transforming the healthcare paradigm in the MENA region by implementing a value-based model that prioritizes personalized health promotion, early disease detection, and integrated care. Al Kalma operates specialized primary care centers and provides comprehensive mental health services, with an initial focus on expanding across Saudi Arabia and the United Arab Emirates. The venture leverages Keralty's global expertise in health risk management and Burjeel's extensive regional infrastructure to improve patient outcomes and reduce hospital dependency.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kalma.